PALVEN: phase 1b trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer
- Author(s)
- Muttiah, C; Whittle, JR; Oakman, C; Lindeman, GJ;
- Journal Title
- Future Oncology
- Publication Type
- epub ahead of print
- Abstract
- The addition of a CDK4/6 inhibitor to endocrine therapy improves progression-free and overall survival in women with metastatic estrogen receptor-positive breast cancer. In that setting, CDK4/6 inhibitors induce a potent cell-cycle arrest (which may be accompanied by tumor senescence) but fail to induce apoptotic cell death. Venetoclax is a potent inhibitor of BCL2, a pro-survival protein overexpressed in the majority of estrogen receptor-positive cancers. Pre-clinical findings indicate that venetoclax augments tumor response to the CDK4/6 inhibitor palbociclib by triggering apoptosis, including in senescent cells. The PALVEN phase 1b trial will further examine this finding. The primary objective is to identify the maximum tolerated dose and determine the recommended phase 2 dose for palbociclib, letrozole and venetoclax combination therapy. Clinical Trial Registration: NCT03900884 (ClinicalTrials.gov).
- Publisher
- Future Medicine
- Research Division(s)
- Cancer Biology And Stem Cells
- PubMed ID
- 35187951
- Publisher's Version
- https://doi.org/10.2217/fon-2021-1450
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2022-03-15 10:53:30
Last Modified: 2022-03-15 11:26:33